Company Overview and News

HOEC rises 4% on completion of two well re-entry, side track drilling

2018-07-13 moneycontrol
Shares of Hindustan Oil Exploration Company (HOEC) added 4.7 percent intraday Friday as company completed two well re-entry and side track drilling campaign which commenced in April 2018.

JK Cement, Omaxe Auto results on Saturday

2018-05-11 thehindubusinessline
The boards of Alkali Metals, Bajaj Hindusthan, Gallant Ispat, Gallant Metal, Hindustan Oil Exploration, JK Cement, LGB Forge, Omaxe Auto, PTC India Financial, Vinati Organics and Vardhman Textiles will meet on Saturday for Q4/FY18 results for the period ended March 2018. The JK Cement board will also consider issuance of NCDs on private placement. SORIL Holdings and Ventures will consider a preferential issue/price for equity shares to foreign investors.
VTL 533007 533029 HINDOILEXP 500820 LGBFORGE ALKALI 524200 502986 VINATIORGA ASIANPAINT 500186

Hindustan Oil Exploration Company (₹129.8): Buy

2018-05-09 premium.thehindubusinessline
The stock of Hindustan Oil Exploration Company has been on a short-term uptrend since taking support at around ₹100 in early March this year.

Tata Group’s business restructuring plan hits a ‘hydrocarbon’ hurdle

2018-04-19 livemint
Mumbai: Tata Petrodyne Ltd, which has put up its six oil and gas blocks for sale, is yet to find interest from buyers, two people aware of the matter said.

Deadline for bidding oil and gas blocks extended to May 2

2018-03-22 thehindubusinessline
The government on Thursday pushed back by a month the last date of bidding for a record number of oil and gas blocks to May 2.

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...